
Biovet Labs Inc., a Los Angeles researcher and developer of animal cancer therapy products, plans to sell up to 1.2 million common shares in an initial public offering. 
Proceeds, estimated at $2.5 million, will be used for marketing, research and development, and for general corporate expenditures, according to a filing with the Securities and Exchange Commission. 